Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 67, Issue 1-2, 2004, Pages 191-200

  Baumann, Fabian ^a   Bjeljac, Miroslava ^a   Kollias, Spyros S ^a   Baumert, Brigitta G ^a   Brandner, Sebastian ^a   Rousson, Valentin ^b   Yonekawa, Yasuhiro ^a   Bernays, René L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antiangiogenic therapy; Brain; Chemotherapy; Glioblastoma multiforme; Survival; Temozolomide; Thalidomide; Treatment

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; CONTRACEPTIVE AGENT; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL DOCUMENTATION; MICROSURGERY; MONOTHERAPY; NEURORADIOLOGY; OPEN STUDY; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SKIN IRRITATION; SOMNOLENCE; SURVIVAL TIME; THROMBOEMBOLISM; TREMOR; TUMOR GROWTH; VERTIGO;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; RADIOTHERAPY; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 1842536794     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000021803.01170.03     Document Type: Article

References (30)

1. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg 95: 190-198, 2001
2. Nieder C, Grosu AL, Molls M: A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26: 397-409, 2000
3. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572, 1999
4. Surawics TS, Davis F, Freels S, Laws ER Jr, Menck HR: Brain tumor survival: results from the National Cancer Data Base. J Neuro-Oncol 40: 151-160, 1998
5. Prados MD, Levin V: Biology and treatment of malignant glioma. Semin Oncol 27: 1-10, 2000
6. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002
7. Forsting M, Albert FK, Kunze S, Adams HP, Zenner D, Sartor K: Extirpation of glioblastomas. MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 14: 77-87, 1993
8. Shrieve DC, Alexander E III, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS: Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90: 72-77, 1999
9. Schiffer D, Chio A, Giordana MT, Mauro A, Migheli A, Vigliani MC: The vascular response to tumor infiltration in malignant gliomas. Morphometric and reconstruction study. Acta Neuropathol (Berl) 77: 369-378, 1989
10. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992
11. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994
12. Fine HA, Figg WD, Jaeckle K, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708-715, 2000
13. Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neuro-Oncol 54: 31-38, 2001
14. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M: Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neuro-Oncol 51: 41-45, 2001
15. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236-2241, 1996
16. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000
17. Stupp R, Dietrich PY, Ostermann KS, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382, 2002
18. Marx J: Angiogenesis. A boost for tumor starvation. Science 301: 452-454, 2003
19. Adlard JW: Thalidomide in the treatment of cancer. Anticancer Drugs 11: 787-791, 2000
20. Singhal S, Mehta J: Thalidomide in cancer: potential uses and limitations. BioDrugs 15: 163-172, 2001
21. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
22. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavanee WK: Pathology and Genetics: Tumours of the Nervous System. IARC Press (International Agency for Research on Cancer), Lyon, France 2000, pp 29-39
23. Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neuro-Oncol 32: 253-265, 1997
24. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 4: 39-43, 2002
25. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, Trinchieri G, Karp CL: Inhibition of IL-12 production by thalidomide. J Immunol 159: 5157-5161, 1997
26. Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L: Thalidomide and thrombosis. Ann Dermatol Venereol 127: 171-174, 2000
27. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV: Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33: 1592-1596, 1997
28. Marras LC, Geerts WH, Perry JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89: 640-646, 2000
29. Chisholm RA, Stenning S, Hawkins TD: The accuracy of volumetric measurement of high-grade gliomas. Clin Radiol 40: 17-21, 1989
30. Xue D, Albright RE Jr: Preoperative anaplastic glioma tumor volume effects on patient survival. J Surg Oncol 72: 199-205, 1999